340B After Genesis and Other Recent Developments: Definition of Patient, Registration of Child Sites, 340B Repayment
Recording of a 90-minute CLE video webinar with Q&A
This CLE webinar will guide healthcare counsel on recent 340B developments. The panel will examine the Genesis decision and its impact on covered entities. The panel will also discuss the Health Resources and Services Administration's (HRSA) notice re: child sites and what it means for child site eligibility as well as the CMS' final rule providing reimbursement for 340B hospitals. The panel will address the implications of these developments for the healthcare industry.
Outline
- Genesis Health Care Inc. v. Becerra and its impact
- Child sites
- HRSA notice
- Recent litigation
- CMS repayment final rule
- Best practices
Benefits
The panel will review these and other key issues:
- What impact will the Genesis decision have for covered entities seeking to use 340B drugs?
- What does the hospitals' challenge of HRSA's child site policy mean for 340B drug use in hospital child sites?
Faculty
Emily J. Cook
Partner
McDermott Will & Emery
Ms. Cook focuses her practice on providing complex regulatory and reimbursement counsel to health care providers... | Read More
Ms. Cook focuses her practice on providing complex regulatory and reimbursement counsel to health care providers including hospitals, health systems, laboratories, durable medical equipment suppliers, ambulatory surgical centers, diagnostic imaging centers and physician practices. She has significant experience counseling health care providers, pharmaceutical manufacturers and group purchasing organizations on issues related to 340B drug pricing program implementation, compliance and advocacy.
Close
Jeffrey I. Davis
Member
Bass Berry & Sims
Mr. Davis advises healthcare organizations on Medicare and Medicaid billing and reimbursement issues, with a special... | Read More
Mr. Davis advises healthcare organizations on Medicare and Medicaid billing and reimbursement issues, with a special focus on the federal 340B drug pricing program. He also counsels clients on emerging healthcare regulatory issues, including COVID-19 relief funding, surprise medical billing, and hospital price transparency, and provides strategic insights to clients on public policy matters under consideration by the U.S. Congress and federal agencies, such as drug pricing policy and nonprofit hospital issues. Mr. Davis forged his deep knowledge of the 340B program and other Medicare and Medicaid reimbursement issues while working in the federal public policy arena. He spent more than seven years working as vice president and legislative and policy counsel for 340B Health, an association of more than 1,400 hospitals and health systems participating in the 340B program. In this role, he provided technical assistance to member hospitals, directed research and policy efforts, and helped lead government relations efforts to educate federal policymakers on 340B issues. Mr. Davis draws on this experience to advise hospitals, pharmacies, other provider organizations and vendors on 340B issues including enrollment, contracting, audits, compliance and self-disclosures.
Close